What is Lifesci Capital’s Forecast for PVLA FY2026 Earnings?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Research analysts at Lifesci Capital decreased their FY2026 EPS estimates for Palvella Therapeutics in a research report issued on Monday, December 15th. Lifesci Capital analyst S. Slutsky now expects that the company will earn ($4.72) per share for the year, down from their previous estimate of ($4.17). The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Monday, November 10th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.18).

A number of other analysts have also weighed in on PVLA. Canaccord Genuity Group raised their target price on Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research note on Tuesday. Chardan Capital upped their target price on shares of Palvella Therapeutics from $110.00 to $174.00 and gave the stock a “buy” rating in a research report on Monday. Craig Hallum began coverage on shares of Palvella Therapeutics in a report on Thursday, December 4th. They issued a “buy” rating and a $175.00 price target for the company. Weiss Ratings restated a “sell (d)” rating on shares of Palvella Therapeutics in a research report on Monday. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $200.00 price target on shares of Palvella Therapeutics in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $155.60.

Palvella Therapeutics Price Performance

PVLA stock opened at $96.24 on Thursday. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of -36.59 and a beta of -0.20. The business has a fifty day moving average price of $85.21 and a 200 day moving average price of $56.66. Palvella Therapeutics has a fifty-two week low of $11.17 and a fifty-two week high of $112.00.

Institutional Investors Weigh In On Palvella Therapeutics

Hedge funds have recently bought and sold shares of the company. Archer Investment Corp acquired a new position in shares of Palvella Therapeutics in the 3rd quarter valued at $28,000. Bank of America Corp DE lifted its holdings in Palvella Therapeutics by 12.3% during the third quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock worth $294,000 after acquiring an additional 515 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Palvella Therapeutics during the third quarter worth about $36,000. JPMorgan Chase & Co. grew its stake in Palvella Therapeutics by 33.7% in the third quarter. JPMorgan Chase & Co. now owns 4,338 shares of the company’s stock valued at $272,000 after acquiring an additional 1,093 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Palvella Therapeutics in the second quarter worth about $37,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $86.23, for a total transaction of $370,961.46. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 20.50% of the stock is owned by corporate insiders.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.